{"id":"f627be7f-191e-465f-ad6f-08da1a44194a","dataset":"sourcesCorporatePublication","time":16,"normalizedUIQL":null,"lastDatasetUpdate":"2019-02-16T00:12:36Z","PagedResults":{"total":81,"firstRow":1,"lastRow":50,"Result":[{"Field":[{"name":"sourceId","type":"string","value":"220172"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Aztec, heprain (oral), Verex, insulin (oral), Verex"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-09-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Verex Laboratories Inc"}],"pos":1},{"Field":[{"name":"sourceId","type":"string","value":"231901"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: CADDYS (growth hormone), Emisphere/Lilly, oral insulin, Emisphere, cromolyn, Emisphere, parathyroid hormone, Emisphere"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-01-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Emisphere Technologies Inc"}],"pos":2},{"Field":[{"name":"sourceId","type":"string","value":"295420"},{"name":"corporatePublicationTitle","type":"string","value":"Cortecs presents phase I oral insulin trial data at Controlled Release Symposium in Stockholm; Cortecs presents phase I oral insulin trial data at Controlled Release Symposium in Stockholm; Planning phase IIa European trial in 3rd quarter"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-08-20T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"PROVALIS Limited"}],"pos":3},{"Field":[{"name":"sourceId","type":"string","value":"312999"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Insulin Sensizer, TPO agonists, EPO agonist, Growth Hormone Modulator, Leptin Modulator, Interleukin Modulators, by Receptron"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-01-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Receptron Inc"}],"pos":4},{"Field":[{"name":"sourceId","type":"string","value":"337500"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: insulin (oral), Protein Delivery Inc"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1999-08-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Protein Delivery Inc"}],"pos":5},{"Field":[{"name":"sourceId","type":"string","value":"357450"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: sucralfate, APCls, insulin analogs, NPC-16377, NPC-16570, NPC-18166, adipsin, heparin-EGF-like factor, cell adhesion inhibitors, bradykinin antagonists, KPI-022, BY-2001"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-02-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Scios Inc"}],"pos":6},{"Field":[{"name":"sourceId","type":"string","value":"372335"},{"name":"corporatePublicationTitle","type":"string","value":"Drug Development Pipeline - AERx (insulin)"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-06-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":7},{"Field":[{"name":"sourceId","type":"string","value":"371716"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: phosphorylated human insulin, Diabecore"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-06-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Diabecore Medical Inc"}],"pos":8},{"Field":[{"name":"sourceId","type":"string","value":"400110"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: insulin glargine"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-02-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Aventis SA"}],"pos":9},{"Field":[{"name":"sourceId","type":"string","value":"407391"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: insulin like growth factor receptor inhibitors"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-04-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Amgen Inc"}],"pos":10},{"Field":[{"name":"sourceId","type":"string","value":"452854"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: insulin (oral), Nobex/GlaxoSmithKline"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-05-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"GlaxoSmithKline plc"}],"pos":11},{"Field":[{"name":"sourceId","type":"string","value":"662549"},{"name":"corporatePublicationTitle","type":"string","value":"Final Appraisal Determination - Long-acting insulin analogues for the treatment of diabetes â€“ insulin glargine"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-10-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE"}],"pos":12},{"Field":[{"name":"sourceId","type":"string","value":"492583"},{"name":"corporatePublicationTitle","type":"string","value":"Novo Nordisk US - Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-06-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":13},{"Field":[{"name":"sourceId","type":"string","value":"583719"},{"name":"corporatePublicationTitle","type":"string","value":"An open label, single arm study to investigate the tolerance, pharmacokinetics and efficacy of a repeated dose of basulin - a new long-acting insulin - in 30 type 1 diabetic patients"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-02-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Flamel Technologies SA"}],"pos":14},{"Field":[{"name":"sourceId","type":"string","value":"602297"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: BN-006, oral GCSF, oral insulin, Diabetology"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-05-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Diabetology Ltd"}],"pos":15},{"Field":[{"name":"sourceId","type":"string","value":"606214"},{"name":"corporatePublicationTitle","type":"string","value":"Novo Nordisk insulin product overview"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-06-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":16},{"Field":[{"name":"sourceId","type":"string","value":"989576"},{"name":"corporatePublicationTitle","type":"string","value":"Clinical Trial Report: A Multinational, Randomized, Controlled, Open-labeled, Parallel Group Evaluation in Terms of Efficacy and Safety of Metformin 1700 mg/day Plus Twice Daily Biphasic Insulin Aspart 30 or Human NPH-insulin in Subjects with Type 2 Diabetes"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-10-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":17},{"Field":[{"name":"sourceId","type":"string","value":"681826"},{"name":"corporatePublicationTitle","type":"string","value":"Pharmacodynamic Properties of VIAject: A Novel Rapid-Acting Regular Human Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-11-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biodel Inc"}],"pos":18},{"Field":[{"name":"sourceId","type":"string","value":"662540"},{"name":"corporatePublicationTitle","type":"string","value":"National Institute for Health and Clinical Excellence: Inhaled insulin for the treatment of diabetes (types 1 and 2) - Appraisal consultation document"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-04-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institute for Health and Clinical Excellence"}],"pos":19},{"Field":[{"name":"sourceId","type":"string","value":"681825"},{"name":"corporatePublicationTitle","type":"string","value":"Pharmacodynamics of VIAject: A Novel Rapid Acting Regular Human Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-06-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biodel Inc"}],"pos":20},{"Field":[{"name":"sourceId","type":"string","value":"988483"},{"name":"corporatePublicationTitle","type":"string","value":"Recombinant Human Pro-insulin C Peptide For Injection"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Newsummit Biopharma Co Ltd"}],"pos":21},{"Field":[{"name":"sourceId","type":"string","value":"805671"},{"name":"corporatePublicationTitle","type":"string","value":"A Randomised, Double-Blind, Placebo-Controlled Trial of Intranasal Insulin (40IU and 440IU) in Children and Young Adults at Risk of Type 1 Diabetes: Intranasal Insulin Trial II (INIT II)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-01-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Royal Melbourne Hospital"}],"pos":22},{"Field":[{"name":"sourceId","type":"string","value":"765924"},{"name":"corporatePublicationTitle","type":"string","value":"Delivery of Biologics - oral insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-02-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MediVas LLC"}],"pos":23},{"Field":[{"name":"sourceId","type":"string","value":"1488399"},{"name":"corporatePublicationTitle","type":"string","value":"HTA Report - Short-acting Insulin Analogues for Diabetes Mellitus: Meta-analysis of Clinical Outcomes and Assessment of Cost-effectiveness"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Canadian Agency for Drugs and Technologies in Health (CADTH)"}],"pos":24},{"Field":[{"name":"sourceId","type":"string","value":"903616"},{"name":"corporatePublicationTitle","type":"string","value":"Product information: Emisphere's oral insulin program"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-04-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Emisphere Technologies Inc"}],"pos":25},{"Field":[{"name":"sourceId","type":"string","value":"1487841"},{"name":"corporatePublicationTitle","type":"string","value":"National Horizon Scanning - Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-12-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Health Service"}],"pos":26},{"Field":[{"name":"sourceId","type":"string","value":"1060682"},{"name":"corporatePublicationTitle","type":"string","value":"Early Communication About Safety of Lantus (insulin glargine)"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-07-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"FDA"}],"pos":27},{"Field":[{"name":"sourceId","type":"string","value":"1075229"},{"name":"corporatePublicationTitle","type":"string","value":"UPDATE: Discontinuation of Humulin 50/50 (50% Human Insulin Isophane Suspension and 50% Human Insulin Injection [rDNA Origin])"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Eli Lilly & Co"}],"pos":28},{"Field":[{"name":"sourceId","type":"string","value":"1073331"},{"name":"corporatePublicationTitle","type":"string","value":"Biodel: Pipeline, BIOD- Smart Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-02-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biodel Inc"}],"pos":29},{"Field":[{"name":"sourceId","type":"string","value":"1075323"},{"name":"corporatePublicationTitle","type":"string","value":"Novo Nordisk is discontinuing several insulin delivery devices"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-02-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":30},{"Field":[{"name":"sourceId","type":"string","value":"1080253"},{"name":"corporatePublicationTitle","type":"string","value":"Insulin initiation in type 2 diabetes"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-03-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novo Nordisk A/S"}],"pos":31},{"Field":[{"name":"sourceId","type":"string","value":"1080209"},{"name":"corporatePublicationTitle","type":"string","value":"Insulin Analogs"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-03-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"New England Healthcare Institute"}],"pos":32},{"Field":[{"name":"sourceId","type":"string","value":"1080451"},{"name":"corporatePublicationTitle","type":"string","value":"Drug datasheet: Humalog Mix75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection)"},{"name":"corporatePublicationType","type":"string","value":"Drug Package Insert"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-03-09T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Eli Lilly & Co"}],"pos":33},{"Field":[{"name":"sourceId","type":"string","value":"1080450"},{"name":"corporatePublicationTitle","type":"string","value":"Drug datasheet: Humalog (insulin lispro injection, USP (rDNA origin) 100 units per ml (U-100))"},{"name":"corporatePublicationType","type":"string","value":"Drug Package Insert"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-03-09T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Eli Lilly & Co"}],"pos":34},{"Field":[{"name":"sourceId","type":"string","value":"1134041"},{"name":"corporatePublicationTitle","type":"string","value":"Pharmacokinetics of novel formulations of insulin analogs providing a more rapid onset of action in the diabetic swine model"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-09-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biodel Inc"}],"pos":35},{"Field":[{"name":"sourceId","type":"string","value":"1211351"},{"name":"corporatePublicationTitle","type":"string","value":"Material safety data sheet : Insulin, Human"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Eli Lilly & Co"}],"pos":36},{"Field":[{"name":"sourceId","type":"string","value":"1215327"},{"name":"corporatePublicationTitle","type":"string","value":"AFREZZA - A Novel Ultra Rapid-Acting Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-08-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Mannkind Corp"}],"pos":37},{"Field":[{"name":"sourceId","type":"string","value":"1485180"},{"name":"corporatePublicationTitle","type":"string","value":"NN304-1938: A Multicenter, Open-label, Non-randomized, Non-interventional, Safety study in Patients With Type 2 Diabetes Treated With Insulin Detemir (Levemir)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-10-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":38},{"Field":[{"name":"sourceId","type":"string","value":"1544426"},{"name":"corporatePublicationTitle","type":"string","value":"A randomized, open-label study of the effect of PEGASYS Â® plus COPEGUSÂ® with or without concomitant pioglitazone (ActosÂ®) on early viral kinetics in treatment-naive patients with chronic hepatitis C, genotype-1, and insulin resistance"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":39},{"Field":[{"name":"sourceId","type":"string","value":"1514957"},{"name":"corporatePublicationTitle","type":"string","value":"Treating Diabetes Using Menin Inhibitors to Regenerate Insulin Producing Beta Cells"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-02-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novapeutics LLc"}],"pos":40},{"Field":[{"name":"sourceId","type":"string","value":"1290723"},{"name":"corporatePublicationTitle","type":"string","value":"APC1 : a novel mechanism for treatment of diabetes type 2 Insulin Replacement Therapy"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-05-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"TwoToBiotech Ltd"}],"pos":41},{"Field":[{"name":"sourceId","type":"string","value":"1308834"},{"name":"corporatePublicationTitle","type":"string","value":"Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-06-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Orgenesis Inc"}],"pos":42},{"Field":[{"name":"sourceId","type":"string","value":"1308836"},{"name":"corporatePublicationTitle","type":"string","value":"Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-06-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Orgenesis Inc"}],"pos":43},{"Field":[{"name":"sourceId","type":"string","value":"1491250"},{"name":"corporatePublicationTitle","type":"string","value":"Novo Nordisk Briefing Document - FDA Endocrinologic and Metabolic Drug Advisory Committee - Insulin Degludec and Insulin Degludec/Insulin Aspart Treatment to Improve Glycemic Control in Patients with Diabetes Mellitus (NDAs 203314 and 203313)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-11-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":44},{"Field":[{"name":"sourceId","type":"string","value":"1487298"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting - Briefing Document for Insulin Degludec and Insulin Degludec/Aspart"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-11-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":45},{"Field":[{"name":"sourceId","type":"string","value":"1513868"},{"name":"corporatePublicationTitle","type":"string","value":"Multicenter, open, non-randomised controlled phase IV clinical trial of efficacy and safety for insulin glulisine injected subcutaneously in patients with type 1 diabetes mellitus using also insulin glargine"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":46},{"Field":[{"name":"sourceId","type":"string","value":"1355810"},{"name":"corporatePublicationTitle","type":"string","value":"Ansulin - Insulin Human (rDNA) USP"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-01-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Square Pharmaceuticals Ltd"}],"pos":47},{"Field":[{"name":"sourceId","type":"string","value":"1383932"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Application;Â  Results for Orphan Drug Product Designations Search: human insulin beta chain peptide with incomplete Freund's adjuvant vaccine; Treatment of Type 1 diabetes patients with residual beta cell function"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":48},{"Field":[{"name":"sourceId","type":"string","value":"1386159"},{"name":"corporatePublicationTitle","type":"string","value":"Insulin SEDICO"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SEDICO Co"}],"pos":49},{"Field":[{"name":"sourceId","type":"string","value":"1386153"},{"name":"corporatePublicationTitle","type":"string","value":"Bioequivalance study of Insulin H Mix 100 IU Suspension"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SEDICO Co"}],"pos":50}]},"DatasetCounts":[],"HitTerms":{"Term":[{"value":"insulin"}],"Synonym":[]},"serviceExecutionTime":23}